Direct Lysis Of Staphylococcus Aureus Resistant Pathogen Trial Of Exebacase

Overview

About this study

The purpose of this study is to evaluate the effectiveness and safety of Exebacase, in addition to standard of care antibiotics (SoCA), compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE). 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female.
  • 18 years or older.
  • Blood culture positive for S. aureus.
  • At least two signs or symptoms attributable to S. aureus BSI/IE.
  • Known or suspected complicated S. aureus BSI and/or right-sided IE based on Modified Duke Criteria.
  • Not pregnant or breastfeeding and not of reproductive potential or agrees to remain abstinent or use contraception if of reproductive potential.

Exclusion Criteria:

  • Previously received exebacase.
  • Known or suspected left-sided IE.
  • Treatment with effective systemic anti-staphylococcal antibiotic for more than 72 hours within 7 days before randomization.
  • Presence of prosthetic valve or cardiac valve support ring, or presence of known or suspected infected orthopedic hardware, prosthetic joint, or cardiac device.
  • Known or suspected brain abscess or meningitis.
  • Known or suspected urinary tract infection or primary pneumonia as the sole source of S. aureus BSI.
  • Known polymicrobial BSI, or known ongoing systemic infection caused by other bacterial and/or fungal pathogen(s).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Zelalem Temesgen, M.D.

Closed for enrollment

Contact information:

Department of Medicine (DOM) Research Hub

(507) 266-1944

DOMRESEARCHHUB@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20509326

Mayo Clinic Footer